ProKidney Corp. (PROK)
| Market Cap | 525.41M +81.3% |
| Revenue (ttm) | 893,000 +1,075.0% |
| Net Income | -68.99M |
| EPS | -0.52 |
| Shares Out | 301.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 335,941 |
| Open | 1.760 |
| Previous Close | 1.770 |
| Day's Range | 1.740 - 1.810 |
| 52-Week Range | 0.540 - 7.130 |
| Beta | 1.75 |
| Analysts | Strong Buy |
| Price Target | 7.40 (+325.29%) |
| Earnings Date | May 26, 2026 |
About PROK
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, a... [Read more]
Financial Performance
In 2025, ProKidney's revenue was $893,000, an increase of 1075.00% compared to the previous year's $76,000. Losses were -$68.99 million, 12.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PROK stock is "Strong Buy." The 12-month stock price target is $7.4, which is an increase of 325.29% from the latest price.
News
ProKidney appoints Greg Madison as chief commercial officer
ProKidney (PROK) announced the appointment of Greg Madison as chief commercial officer. In this role, Madison will drive ProKidney’s commercial strategy as the company advances towards the potential c...
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney dise...
ProKidney reports Q4 EPS (52c), consensus (15c)
Reports Q4 revenue $893,000, consensus $600,000. “2025 was a pivotal year for ProKidney (PROK), highlighted by positive Phase 2 REGEN-007 study results, alignment with the FDA on the accelerated appro...
ProKidney Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rilparencel, an autologous cell therapy, is advancing through a pivotal phase III trial for advanced CKD, with top-line data expected in Q2 2027. Phase II results showed significant improvement in kidney function and strong safety, while manufacturing and commercial preparations are underway.
ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference
WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney (PROK) with a Buy rating and $12 price target The company is pioneering an approach to postponing progressive kidney dysfunctio...
ProKidney Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company is advancing an autologous cell therapy for advanced CKD, with phase III trials over 50% enrolled and an accelerated approval readout expected in Q2 2027. Strong phase II data, a robust safety profile, and significant market potential support commercial prospects.
ProKidney reports Q3 EPS (12c), consensus (14c)
Reports Q3 revenue $217,000, consensus $44,250. “The Phase 2 REGEN-007 full results recently presented at ASN Kidney Week further strengthen the body of evidence supporting our ongoing Phase 3 PROACT…
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disea...
ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
ProKidney (PROK) presented full results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with advanced CKD and diabetes. The data, featured in a late-breaking clinical trials presen...
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
WINSTON-SALEM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented...
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
WINSTON-SALEM, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The conference highlighted significant progress in the Phase III program for advanced CKD, including FDA alignment on accelerated approval using eGFR slope and a robust effect size. Financially, the company is well-funded through mid-2027, with a large addressable market and strong manufacturing capabilities.
ProKidney Transcript: Citi's Biopharma Back to School Conference
Phase II data showed a significant reduction in kidney function decline with rilparencel, and detailed results will be presented at ASN Kidney Week. The phase III PROACT 1 trial is over 50% enrolled, targeting advanced CKD, with accelerated approval readout expected in Q2 2027.
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney reports Q2 EPS (13c), consensus (14c)
“We’ve made tremendous progress in 2025, and July was a pivotal month for ProKidney (PROK) with the release of positive topline data from our Phase 2 REGEN-007 study and alignment…
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
WINSTON-SALEM, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapeutics company focused on chronic kidney ...
Prokidney Corp options imply 15.7% move in share price post-earnings
Pre-earnings options volume in Prokidney (PROK) Corp is normal with puts leading calls 9:4. Implied volatility suggests the market is anticipating a move near 15.7%, or 38c, after results are…
Prokidney Corp options imply 13.0% move in share price post-earnings
Pre-earnings options volume in Prokidney (PROK) Corp is normal with calls leading puts 12:1. Implied volatility suggests the market is anticipating a move near 13.0%, or 35c, after results are…
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Microbot Medical (MBOT) 82.20% +3.42, BIT Mining Ltd (BTCM) 107.59% +3.17, Prokidney Corp (PROK) 158.5...
ProKidney announces alignment with FDA on rilparencel accelerated approval path
ProKidney (PROK) announced confirmation of alignment with the U.S. Food and Drug Administration on the accelerated approval pathway for rilparencel. Rilparencel is an autologous cellular therapy that ...
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kid...
ProKidney price target raised to $8 from $4 at UBS
UBS raised the firm’s price target on ProKidney (PROK) to $8 from $4 and keeps a Buy rating on the shares. Recent data from a Phase 2 trial of rilparencel…
ProKidney Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference
A cell therapy for advanced CKD showed strong Phase II results, with a 78% improvement in eGFR decline and plans for accelerated approval based on a single Phase III trial. Manufacturing and commercial readiness are in place, with key data and regulatory updates expected in the next year.